Purpose: To investigate the potential added value of paclitaxel-coated balloon (PCB) angioplasty to reduce fistula dysfunction related to recurrent stenoses in patients undergoing hemodialysis.
Materials And Methods: A prospective, randomized study was conducted in 3 dialysis referral centers. From January 2013 to October 2015, 64 patients (22 female, 42 male) with dysfunctional autologous dialysis fistulae were randomized to undergo conventional percutaneous balloon angioplasty (n = 31) or PCB angioplasty (n = 33). Procedural and postprocedural data were assessed. Primary patency of the fistula was evaluated at 3, 6, and 12 months following the procedure. Statistical analysis was based on the Fisher exact test and independent t test.
Results: There were no procedural or postprocedural complications. After 3, 6, and 12 months of follow-up, primary patency rates after PCB angioplasty and percutaneous transluminal angioplasty (PTA) were 88% and 80% (P = .43), 67% and 65% (P = .76), and 42% and 39% (P = .95), respectively.
Conclusions: Although primary patency rates after PCB angioplasty in autologous dialysis fistulae at 3, 6, and 12 months of follow-up are slightly better than those after PTA, the difference is not statistically significant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvir.2017.10.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective cohort study on the safety and efficacy of paclitaxel-coated balloon in the treatment of diabetic subpatellar artery disease.
Medicine (Baltimore)
December 2024
Mindong Hospital Affiliated to Fujian Medical University, Interventional Vascular Surgery, Ningde, Fujian, China.
Paclitaxel can inhibit smooth muscle cell proliferation and migration, and reduce the risk of vascular restenosis after balloon dilation. Our study investigated the safety and efficacy of paclitaxel-coated balloon (PCB) treatment for diabetic subpatellar artery disease. In this study, 140 patients with diabetic subknee arterial disease treated in our hospital from January 2022 to December 2023 were selected as the study objects, and were divided into the control group (conventional balloon interventionization angioplasty) and the observation group (PCB interventionization angioplasty), with 70 cases in each group according to the differences in previous balloon interventionization.
View Article and Find Full Text PDFResults of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months.
Eur J Vasc Endovasc Surg
November 2024
Vascular Medicine and Intervention, Massachusetts General Hospital, Boston, MA, USA.
Article Synopsis
- * In this randomized controlled trial involving 446 patients, the SurVeil PCB showed a primary safety rate of 91.8% and a primary efficacy rate of 82.2%, while the IN.PACT Admiral had rates of 89.8% and 85.9%, respectively.
- * The results indicate that the SurVeil PCB is a safe and effective treatment option, demonstrating non-inferiority to the IN.PACT Admiral PCB over a 24-month period.
A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions.
EuroIntervention
November 2024
Protestant Hospital Paul Gerhardt Stift, Lutherstadt Wittenberg, Germany.
Article Synopsis
- Paclitaxel-coated balloons (PCB) are currently used for treating coronary lesions, but researchers are exploring sirolimus-coated balloons (SCB) as an alternative to see if they perform similarly.
- A study involving 70 patients across Germany and Switzerland tested the SCB against PCB, focusing on their effectiveness in preventing late lumen loss (LLL) in arteries after 6 months.
- Results indicated no significant differences between the two treatments in terms of LLL and clinical outcomes, suggesting that SCBs can be a viable alternative to PCBs in coronary interventions.
Treatment of Patients With De Novo Small-Vessel Coronary Lesions: Analysis of Six Randomised Controlled Trials Comparing Paclitaxel-Coated Balloons With Drug-Eluting Stents.
Cureus
September 2024
Health Technology Assessment Unit, Regione Toscana, Florence, ITA.
Both paclitaxel-coated balloons (PCB) and drug-eluting stents (DES) are indicated for the treatment of de novo small-vessel coronary lesions. Since the evidence comparing these two types of devices is limited, we undertook a meta-analysis on this issue. Our meta-analysis compared the efficacy of PCB vs.
View Article and Find Full Text PDFComparative long-term efficacy and safety of two paclitaxel-coated balloons with different coating strategies for the treatment of drug-eluting coronary stent restenosis.
Catheter Cardiovasc Interv
November 2024
ISAResearch Zentrum, Kardiologie, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
Background: We previously showed non-inferiority of a low-dose paclitaxel-coated balloon (PCB) with citrate excipient (Agent PCB) as compared to normal-dose iopromide excipient (SeQuent Please PCB) in terms of angiographic and clinical endpoints at 12 months. The long-term clinical efficacy and safety of Agent PCB is not defined.
Methods: 262 patients (323 DES-ISR lesions) were enrolled in this study and treated with either Agent PCB (125 patients, 151 lesions) in the ISAR-DESIRE 3a trial or with SeQuent Please PCB (137 patients, 172 lesions) in the setting of the randomized ISAR-DESIRE 3 trial with similar in- and exclusion criteria serving as historical control arm.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!